NEULANDLAB - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 3.8
| Stock Code | NEULANDLAB | Market Cap | 17,167 Cr. | Current Price | 13,392 ₹ | High / Low | 19,748 ₹ |
| Stock P/E | 88.0 | Book Value | 1,257 ₹ | Dividend Yield | 0.09 % | ROCE | 18.7 % |
| ROE | 14.8 % | Face Value | 10.0 ₹ | DMA 50 | 14,649 ₹ | DMA 200 | 14,364 ₹ |
| Chg in FII Hold | 0.30 % | Chg in DII Hold | 1.17 % | PAT Qtr | 96.5 Cr. | PAT Prev Qtr | 13.7 Cr. |
| RSI | 41.7 | MACD | -589 | Volume | 36,152 | Avg Vol 1Wk | 44,194 |
| Low price | 10,060 ₹ | High price | 19,748 ₹ | PEG Ratio | 1.86 | Debt to equity | 0.16 |
| 52w Index | 34.4 % | Qtr Profit Var | 202 % | EPS | 187 ₹ | Industry PE | 29.2 |
📊 NEULANDLAB shows moderate potential for swing trading. The stock is currently at 13,392 ₹, trading below both its 50 DMA (14,649 ₹) and 200 DMA (14,364 ₹), reflecting short-term weakness. RSI at 41.7 suggests the stock is approaching oversold territory, while MACD at -589 confirms bearish momentum. Fundamentals are decent with ROCE at 18.7% and ROE at 14.8%, supported by strong EPS of 187 ₹ and impressive quarterly PAT growth (13.7 Cr. → 96.5 Cr.). However, valuation is stretched (P/E 88.0 vs industry 29.2, PEG 1.86), dividend yield is negligible (0.09%), and trading volume remains low.
✅ Optimal Entry Price: 13,200–13,400 ₹ (near support zone)
🚪 Exit Strategy (if already holding): Consider profit booking around 14,500–14,700 ₹ (near 50 DMA resistance), or exit if price falls below 13,000 ₹ with strong volume.
Positive
- 💡 Strong EPS of 187 ₹ reflects earnings power.
- 📊 Quarterly PAT growth of 202% (13.7 Cr. → 96.5 Cr.).
- 📈 ROCE (18.7%) and ROE (14.8%) show decent efficiency.
- 📦 Debt-to-equity ratio of 0.16 indicates manageable leverage.
- 📈 FII holding increased by 0.30% and DII holding by 1.17%, showing institutional confidence.
Limitation
- ⚠️ High P/E of 88.0 vs industry average of 29.2.
- 📉 PEG ratio of 1.86 suggests expensive growth valuation.
- 🔻 Dividend yield of only 0.09% offers negligible income support.
- 📉 Trading below both 50 DMA and 200 DMA, showing weak momentum.
- 📉 Low trading volume compared to weekly average.
Company Negative News
- 📉 Stock momentum remains weak with RSI at 41.7 and MACD at -589.
- 🚫 Valuation stretched compared to peers.
Company Positive News
- 📊 PAT improved significantly (13.7 Cr. → 96.5 Cr.).
- 📈 Institutional inflows (FII +0.30%, DII +1.17%) reflect confidence.
- 📈 EPS strength supports long-term investor interest.
Industry
- 🏭 Industry P/E at 29.2 indicates sector is moderately valued.
- 📦 Pharma sector benefits from global demand for APIs and specialty drugs.
Conclusion
⚖️ NEULANDLAB is a fundamentally decent company with strong earnings growth but faces stretched valuations and weak short-term momentum. Entry near 13,200–13,400 ₹ offers a cautious swing setup, with exit targets around 14,500–14,700 ₹. Risk management is essential if price breaks below 13,000 ₹, as momentum could weaken further.